Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats

Cardiovasc Res. 2016 Jun 1;110(3):371-80. doi: 10.1093/cvr/cvw071. Epub 2016 Mar 31.

Abstract

Aims: Type 2 diabetes (T2D) is an independent risk factor for atrial fibrillation (AF) and stroke. The serine protease cathepsin A (CatA) is up-regulated in diabetes and plays an important role in the degradation of extracellular peptides. This study sought to delineate the role of CatA for the development of atrial remodelling under diabetic conditions.

Methods and results: Zucker Diabetic Fatty rats (ZDF) were treated with vehicle (n = 20) or CatA-inhibitor (SAR; 50 mg/kg; n = 20), and compared with age-matched non-diabetic littermates (Ctr, n = 20). Left-atrial (LA) emptying function [magnetic resonance imaging (MRI)] and atrial electrophysiological parameters were measured before sacrifice for histological and biochemical analysis. The impact of enhanced cardiac CatA expression on atrial remodelling was determined using CatA-transgenic mice. At the age of 9.5 months, atrial tissues of ZDF rats showed increased CatA gene expression and CatA-activity, along with increased AF-susceptibility and impaired LA-emptying function. CatA-inhibition reduced CatA-activity in ZDF comparable to Ctr values and decreased LA-fibrosis formation and connexin 43 lateralization. This was associated with shorter median duration of LA-tachyarrhythmia (12.0 ± 1.7 vs. 1.2 ± 0.47 s, P < 0.01) induced by burst pacing and diminished regions of slow conduction. Cardiac MRI revealed better LA-emptying function parameters (active per cent emptying: 29 ± 1 vs. 23 ± 2%, P < 0.01) after CatA-inhibition. CatA-inhibition reduced LA bradykinin-degrading activity in ZDF. Transgenic mice overexpressing CatA demonstrated enhanced atrial fibrosis formation and increased AF-susceptibility.

Conclusion: T2D leads to arrhythmogenic atrial remodelling in ZDF rats. CatA-inhibition reduces LA bradykinin-degrading activity in ZDF and suppresses the development of atrial structural changes and AF-promotion, implicating CatA as an important mediator for AF-substrate in T2D.

Keywords: Atrial emptying function; Atrial fibrillation; Cathepsin A; Diabetes; Remodelling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Angiotensin II / metabolism
  • Animals
  • Atrial Fibrillation / enzymology*
  • Atrial Fibrillation / genetics
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / prevention & control
  • Atrial Function, Left* / drug effects
  • Atrial Remodeling* / drug effects
  • Bradykinin / metabolism
  • Cathepsin A / antagonists & inhibitors
  • Cathepsin A / genetics
  • Cathepsin A / metabolism*
  • Connexin 43 / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / enzymology*
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / physiopathology
  • Disease Models, Animal
  • Fibrosis
  • Heart Rate
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Myocardium / enzymology*
  • Protease Inhibitors / pharmacology
  • Rats, Zucker
  • Time Factors

Substances

  • Connexin 43
  • Gja1 protein, rat
  • Protease Inhibitors
  • Angiotensin II
  • CTSA protein, human
  • Cathepsin A
  • Bradykinin